Integra Lifesciences Holdings Corp.
- IART ยท Nasdaq
- Surgical & Medical Instruments & Apparatus
- Princeton, NJ
- 4,427 employees
- CIK 0000917520
Updated from SEC filings through
Top things to know
Executives
- Stuart Essig Chairman and Chief Executive Officer 8-K, 2026-10-21
- Mojdeh Poul President & CEO 4, 2026-03-12
-
Lea Daniels Knight EVP & Chief Financial Officer 4, 2026-07-06 - Lesha R. Shinn CVP, Chief Legal Officer & Sec 3, 2026-09-28
-
Harvinder Singh EVP & President, SS 4, 2026-07-06 -
Robert T. Davis Jr. EVP & President, TR&DT 4, 2026-07-06
What leadership is saying
“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing”
Earnings press release (8-K Ex. 99.1), filed October 21, 2026
Integra Lifesciences Holdings Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Princeton, NJ. It trades as IART on Nasdaq. Revenue was $1.6B in the fiscal year ending December 31, 2025, +1.5% from the year before. It reported about 4,427 employees. Stuart Essig is Chairman and Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.6B 10-K, 2026-02-26 | $1.6B 10-K, 2026-02-26 | $1.5B 10-K, 2026-02-26 | $1.6B 10-K, 2025-02-25 | $1.5B 10-K, 2024-02-28 |
| Operating income | -$493M 10-K, 2026-02-26 | $28.4M 10-K, 2026-02-26 | $112M 10-K, 2026-02-26 | $239M 10-K, 2025-02-25 | $197M 10-K, 2024-02-28 |
| SG&A | $700M 10-K, 2026-02-26 | $717M 10-K, 2026-02-26 | $657M 10-K, 2026-02-26 | $616M 10-K, 2025-02-25 | $637M 10-K, 2024-02-28 |
| Net income | -$516M 10-K, 2026-02-26 | -$6.9M 10-K, 2026-02-26 | $67.7M 10-K, 2026-02-26 | $181M 10-K, 2025-02-25 | $169M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Stuart Essig Chairman and Chief Executive Officer, Integra LifeSciences | Chairman and Chief Executive Officer | 8-K, 2026-10-21 |
| Mojdeh Poul | President & CEO | 4, 2026-03-12 |
| Lea Daniels Knight | EVP & Chief Financial Officer | 4, 2026-07-06 |
| Lea Knight | Named in proxy bio: Executive Vice President and Chief Financial Officer | DEF 14A, 2026-04-06 |
| Lesha R. Shinn VP & Deputy General Counsel | Life Sciences and Med Tech Legal Executive | Corporate Governance & Securities | M&A and Strategic Transactions | CVP, Chief Legal Officer & Sec | 3, 2026-09-28 |
| Harvinder Singh Executive Vice President & President Specialty Surgery | EVP & President, SS | 4, 2026-07-06 |
| Robert T. Davis Jr. | EVP & President, TR&DT | 4, 2026-07-06 |
 Michael J. McBreen | EVP & Chief Commercial Officer | 4, 2026-06-03 |
| Chantal Veillon EVP & Chief Human Resources Officer | Named in proxy bio: Executive Vice President and Chief Human Resources Officer | DEF 14A, 2026-04-06 |
| Michael McBreen | Named in proxy bio: Executive Vice President, President, Codman Specialty Surgical | DEF 14A, 2026-04-06 |
| Michael Hutchinson | Named in proxy bio: Executive Vice President, Chief Legal Officer and Secretary | DEF 14A, 2026-04-06 |
| Michael Damon Hutchinson | EVP, Chief Legal Officer & Sec | 4, 2026-03-12 |
| Andrea B. Caruso | CVP & CHRO | 3, 2026-10-13 |
| Chantal Veillon-Berteloot | EVP & CHRO | 4, 2026-09-04 |
| Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | 4, 2026-07-06 |
| Barbara B. Hill | Board member (per proxy) bio: director | DEF 14A, 2026-04-06 |
What Integra Lifesciences Holdings Corp does
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 77.8 million (as of October 22, 2026) | 10-Q, October 23, 2026 |
|---|---|---|
| Public float | $925M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 2 (period ending September 30, 2026) | 10-Q, October 23, 2026 |
| Latest proxy statement | Meeting December 31, 2025 (filed April 6, 2026) | DEF 14A, April 6, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Florham Park, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 5, 2025 | Jeffrey A. Graves Director | Buy | 9,000 | $102K | Form 4, November 6, 2025 |
Recent 8-K events
- 8-K filed 2026-10-21
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-19
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-09
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-02
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-08
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-08
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-05
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-15
- Item 1.01 Entry into a material definitive agreement
Frequently asked questions about Integra Lifesciences Holdings Corp
- What does Integra Lifesciences Holdings Corp do?
- In its own words, from Item 1 of its 10-K: "Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care."
- What is Integra Lifesciences Holdings Corp's revenue?
- $1.6B for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Integra Lifesciences Holdings Corp profitable?
- Integra Lifesciences Holdings Corp reported net income of -$516M for the fiscal year ending December 31, 2025.
- How many employees does Integra Lifesciences Holdings Corp have?
- About 4,427, as stated in its annual report.
- Who is the CEO of Integra Lifesciences Holdings Corp?
- Stuart Essig, Chairman and Chief Executive Officer, as named in a 8-K filed October 21, 2026.
- Who is the CFO of Integra Lifesciences Holdings Corp?
- Lea Daniels Knight, EVP & Chief Financial Officer, as named in a 4 filed July 6, 2026.
- Where is Integra Lifesciences Holdings Corp headquartered?
- Princeton, NJ.
- What is Integra Lifesciences Holdings Corp's stock ticker?
- IART on Nasdaq.
- What industry is Integra Lifesciences Holdings Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Integra Lifesciences Holdings Corp's website?
- integralife.com.
- When does Integra Lifesciences Holdings Corp report earnings next?
- January 14, 2027. Source: estimate_8k_pattern.
- Is Integra Lifesciences Holdings Corp a public company?
- Yes. Integra Lifesciences Holdings Corp files with the SEC under CIK 0000917520 and trades as IART.
- Who audits Integra Lifesciences Holdings Corp?
- PricewaterhouseCoopers LLP, Florham Park, New Jersey, as named in its latest annual report (10-K).
- How many shares of Integra Lifesciences Holdings Corp are outstanding?
- 77.8 million shares as of October 22, 2026, from its 10-Q filed October 23, 2026.
- What is Integra Lifesciences Holdings Corp's public float?
- $925M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Integra Lifesciences Holdings Corp report?
- 2 reportable segments for the period ending September 30, 2026, from its 10-Q filed October 23, 2026.
- When is Integra Lifesciences Holdings Corp's annual shareholder meeting?
- December 31, 2025, per its proxy statement (DEF 14A) filed April 6, 2026.
- Have Integra Lifesciences Holdings Corp insiders traded stock recently?
- Since November 5, 2025, officers and directors reported 0 open-market sales and 1 purchase worth about $102K on Forms 4 and 5. The most recent: Jeffrey A. Graves (Director) bought 9,000 shares on November 5, 2025.